RLP 068

Drug Profile

RLP 068

Alternative Names: RLP068; RLP068/Cl; VULNOFAST; VULNOFAST Gel; VULNOFAST Plus

Latest Information Update: 21 Jul 2015

Price : $50

At a glance

  • Originator Molteni Therapeutics
  • Class Antibacterials; Antifungals; Phthalocyanines; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin ulcer; Wound infections

Most Recent Events

  • 27 Jul 2010 Phase-II clinical trials in Wound infections in Italy (Topical)
  • 27 Aug 2007 Preclinical development is ongoing
  • 27 Aug 2007 Molteni Therapeutics seeks partnerships to further develop candidates from this research programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top